Ongoing coronavirus (COVID-19) updates and resources for integrative healthcare professionals
Latest news updates and statistics
The latest news updates from Integrative Practitioner include:
- Differing immune system variation may predict severe COVID-19 outcomes. Click here for more information.
- FDA issues emergency authorization for new COVID-19 antibody tests. Click here for more information.
- Young kids spread COVID-19 as much as adults, study finds. Click here for more information.
- New bill introduced to permanently extend telehealth services. Click here for more information.
- Study finds high COVID-19 risk among healthcare workers, especially those from minority backgrounds. Click here for more information.
- Johnson & Johnson vaccine shows protection in pre-clinical trials. Click here for more information.
- Study of COVID-19 vaccine supports advance to phase 3 human trials. Click here for more information.
The total number confirmed cases as press time, according to the John’s Hopkins University Coronavirus Resource Center, is 18,364,694 with the largest number of cases coming from the following countries:
- 4,742,277 cases in the U.S.
- 2,750,318 cases in Brazil
- 1,855,745 cases in India
- 859,762 cases in Russia
- 516,862 cases in South Africa
- 443,813 cases in Mexico
- 433,100 cases in Peru
- 362,962 cases in Chile
- 327,850 cases in Colombia
- 314,786 cases in Iran
- 307,256 cases in the United Kingdom
- 302,814 cases in Spain
- 281,456 cases in Saudi Arabia
- 280,461 cases in Pakistan
- 248,419 cases in Italy
- 244,020 cases in Bangladesh
- 234,934 cases in Turkey
- 228,574 cases in France
- 212,669 cases in Germany
- 206,743 cases in Argentina
- 134,722 cases in Iraq
- 119,170 cases in Canada
- 115,056 cases in Indonesia
- 112,593 cases in Philippines
- 111,538 cases in Qatar
There are currently 159,802 deaths linked to COVID-19 in the U.S. and 2,463,983 have recovered. Click here for the latest statistics provided by Johns Hopkins University.
There are currently over 100 vaccine programs underway worldwide. The three front-runners are ChAdOx1 nCoV-19 developed by Oxford University and AstraZeneca, an mRNA vaccine developed by Moderna, and Ad5-nCoV developed by CanSino Biologics. All three produced promising immune responses in early clinical trials.
Johnson & Johnson's experimental vaccine was also found to protect against SARS-CoV-2 infection.
In July, the pharmaceutical giant Pfizer and German biotechnology company BioNTech received a $1.95 billion grant to produce 100 million doses of a coronavirus vaccine by December 2020.
Click here to track COVID-19 vaccine development in real time. Other promising vaccine trials include:
- Arcturus and Duke-NUS Medical School
- Johnson & Johnson
- Kentucky BioProcessing
- Gamaleya Research Institute
The National Institutes of Health announced July 23 it was preparing to launch several large clinical trials to test new approaches to treating COVID-19.
While there is currently no definitive treatment for COVID-19, a May 2020 report found remdesivir more effective than a placebo for shortening recovery times in adults hospitalized with the virus. Additionally, dexamethasone, a steroid, prolonged survival in the sickest patients in a study conducted in the U.K.